Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
Conditions: Age Range ≥16 Years, Gender Unlimited; Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma; Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed; At Least One Positive Lesion According to the 20 14 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma; ECOG Physical Status Score is 0-3; The Researchers Judged That Life Expectancy Was at Least Three Months; Understand and Voluntarily Sign Written Informed Consent Intervention: Drug: TR2-ICE Sponsors: Affiliated Hospital to Academy of Military Medical Sciences; Beijing Cancer Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | Chemotherapy | China Health | Hospitals | Lymphoma | Non-Hodgkin's Lymphoma | Research